Highlights Ryvu Therapeutics S.A.

Equities

RVU

PLSELVT00013

Delayed Warsaw S.E. Other stock markets 05:28:57 2024-04-30 am EDT			5-day change	1st Jan Change
48.7 ^PLN	-0.31%		-4.13%	-15.30%

Mar. 13	Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	Mar. 06	CI
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	Feb. 14	CI
Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml	Jan. 31	CI
Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023	Dec. 07	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120	23-10-23	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-13	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	22-12-11	CI
BioNTech Forms Multi-Target Research Collaboration With Ryvu Therapeutics	22-11-30	MT
BioNTech to Make $21 Million Equity Investment in Ryvu Therapeutics	22-11-30	MT
BioNTech SE and Ryvu Therapeutics S.A. Enters into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates	22-11-30	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-22	CI
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	22-11-03	CI
Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium	22-10-26	CI
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-28	CI
Poland's Ryvu Therapeutics Bags $22 Million EU Financing To Develop New Cancer Drugs	22-08-17	MT
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association Congress	22-06-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ryvu Therapeutics S.A.

Equities

RVU

PLSELVT00013

Highlights

Filters